CEROW
Income statement / Annual
Last year (2023), CERo Therapeutics Holdings, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, CERo Therapeutics Holdings, Inc.'s net income was -$2,536.23.
See CERo Therapeutics Holdings, Inc.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
Gross Profit |
$0.00
|
$0.00
|
$0.00
|
Gross Profit Ratio |
0
|
0
|
0
|
Research and Development Expenses |
$0.00
|
$9.85 M
|
$9.14 M
|
General & Administrative Expenses |
$2,892.94
|
$2.13 M
|
$2.48 M
|
Selling & Marketing Expenses |
$2.89 M
|
$715,763.00
|
-$2.23 M
|
Selling, General & Administrative Expenses |
$2.89 M
|
$2.84 M
|
$251,705.00
|
Other Expenses |
$40,050.00
|
-$64,050.00
|
-$80,320.00
|
Operating Expenses |
$2.93 M
|
$2.91 M
|
$332,026.00
|
Cost And Expenses |
$2.93 M
|
$2.91 M
|
$332,030.00
|
Interest Income |
$491,571.00
|
$142,115.00
|
$986,711.00
|
Interest Expense |
$0.00
|
$0.00
|
$0.00
|
Depreciation & Amortization |
$2,932.99
|
$1.07 M
|
$735,473.00
|
EBITDA |
-$2.44 M |
-$68,577.00 |
-$332,030.00 |
EBITDA Ratio |
0
|
0
|
0
|
Operating Income Ratio |
0
|
0
|
0
|
Total Other Income/Expenses Net |
$491,571.00
|
$2.84 M
|
$99,081.00
|
Income Before Tax |
-$2.44 M
|
-$68,577.00
|
-$332,415.00
|
Income Before Tax Ratio |
0
|
0
|
0
|
Income Tax Expense |
$94,819.00
|
$599,159.00
|
-$16,868.00
|
Net Income |
-$2,536.23
|
-$667,736.00
|
-$315,547.00
|
Net Income Ratio |
0
|
0
|
0
|
EPS |
-0.39 |
-0.0986 |
-0.0137 |
EPS Diluted |
-0.39 |
-0.0986 |
-0.0137 |
Weighted Average Shares Out |
$6.53 M
|
$6.77 M
|
$22.98 M
|
Weighted Average Shares Out Diluted |
$6.53 M
|
$6.77 M
|
$22.98 M
|
Link |
|
|
|